ORIGINAL ARTICLEInvestigation of the efficacy of generic and brand-name Tiotropium bromide (cas 136310-93-5) in the management of chronic obstructive pulmonary disease: A randomized comparative trial
-
Add time:09/07/2019 Source:sciencedirect.com
Introduction: The beneficial effects of Tiotropium bromide (cas 136310-93-5), a long acting anticholinergic bronchodilator, in the management of chronic obstructive pulmonary disease have been shown in previous studies. The present study aimed to compare the efficacy and safety of generic (Tiova®) and brand-name (Spiriva®) tiotropium preparations in patients with COPD. Methods and materials: In this randomized double-blind parallel-group trial, 79 patients with documented COPD were assigned to Tiova® or Spiriva® for a period of 4 weeks. Assessment of pulmonary function (using spirometry), quality-of-life (using St. George respiratory Questionnaire [SGRQ]) and severity of respiratory symptoms (using breathlessness, cough and sputum scale [BCSS]) was performed at baseline and at the end of treatment period. Results: There were significant increases in FEV1 and reductions in FVC by the end of study in both Tiova® and Spiriva® groups. FEV1/FVC ratio did not change significantly neither in the Tiova® nor in Spiriva® group. Overall SGRQ score as well as subscale scores of symptoms, activity and impacts were improved by both drugs. In the BCSS scale, the frequency and severity of three main symptoms (dyspnea, cough and sputum) was decreased by both drugs. Baseline as well as post-treatment values of spirometric parameters, SGRQ and BCSS scores was comparable between the groups, apart from a lower post-treatment frequency of cough and sputum in the Spiriva® versus Tiova® group. There was no report of adverse events in either of the study groups. Conclusion: The findings of this comparative trial showed equivalent efficacy and safety of Spiriva® and Tiova® in lessening the symptoms as well as improving the quality of life in patients with COPD. This finding has an important translational value given the significantly lower costs of generic versus brand-name products.
We also recommend Trading Suppliers and Manufacturers of Tiotropium bromide (cas 136310-93-5). Pls Click Website Link as below: cas 136310-93-5 suppliers
Prev:Original articleAsthma, lower airway diseasesEffect of Tiotropium bromide (cas 136310-93-5) on airway remodeling in a chronic asthma model
Next:Crystal and molecular structure of N-methylpiperidine betaine hydrochloride) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Original articleAsthma, lower airway diseasesEffect of Tiotropium bromide (cas 136310-93-5) on airway remodeling in a chronic asthma model09/06/2019
- Review articleTiotropium in asthma: From bench to bedside09/05/2019
- ReviewsTiotropium bromide (cas 136310-93-5)09/04/2019
- Tiotropium bromide (cas 136310-93-5) inhibits relapsing allergic asthma in BALB/c mice☆09/03/2019
- Original articleComparison of the rapid effects of single inhalations of formoterol and Tiotropium bromide (cas 136310-93-5) on respiratory function and COPD symptoms in a randomized crossover study09/02/2019
- Effects of Tiotropium bromide (cas 136310-93-5) on airway hyperresponsiveness and inflammation in mice exposed to organic dust09/01/2019
- Evaluation of patients’ real-world post-dispensing use and storage environments of Tiotropium bromide (cas 136310-93-5) Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition08/31/2019
- Pharmacological characterization of the interaction between Tiotropium bromide (cas 136310-93-5) and olodaterol on human bronchi and small airways08/30/2019
-
Health and Chemical more >
-
Related Products